MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
GRFS stock logo

GRFS

Grifols, S.A.

$8.24
-0.01
 (-0.12%)
Exchange:  NASDAQ
Market Cap:  6.971B
Shares Outstanding:  421.254M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – General
   
CEO:  Jose Ignacio Abia Buenache
Full Time Employees:  23833
Address: 
Avinguda de la Generalitat, 152
Barcelona
8174
ES
Website:  https://www.grifols.com
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/12 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue6,591,9777,212,3827,227,047.987
Gross Profit2,483,4822,794,5382,579,990.815
EBITDA1,169,5031,484,4641,619,458.120
Operating Income782,3171,192,0151,187,218.408
Net Income42,318156,920386,134.142

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets21,441,05421,405,24119,749,590.896
Total Liabilities13,468,56912,798,21612,133,833.580
Total Stockholders Equity5,827,1665,883,7275,268,756.636
Total Debt10,117,43910,085,6198,740,278.509
Cash and Cash Equivalents529,577979,780824,648.875

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow208,283902,1681,005,677.730
Capital Expenditure-295,420-371,367-254,541.161
Free Cash Flow-87,137530,801751,136.568
Net Income59,315443,996386,134.142
Net Change in Cash-18,402450,203-38,845.004

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)9,615,403.195Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)10,011,976.630Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)9,790,576.058Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)2,496,713.312Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)2,599,686.651Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)2,542,198.291Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)1,188,699.647Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)1,252,782.618Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)1,217,004.774Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)1,711,046.732Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,781,616.386Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,742,218.483Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.790Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.840Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)1.750Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)3Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
7.802B  ?P/S
 (TTM)
: 
0.87
?Net Income
 (TTM)
: 
169.739M  ?P/E
 (TTM)
: 
16.51
?Enterprise Value
 (TTM)
: 
15.382B  ?EV/FCF
 (TTM)
: 
19.67
?Dividend Yield
 (TTM)
: 
0.02  ?Payout Ratio
 (TTM)
: 
0.32
?ROE
 (TTM)
: 
0.08  ?ROIC
 (TTM)
: 
0.06
?Net Debt
 (TTM)
: 
8.513B  ?Debt/Equity
 (TTM)
: 
1.83
?P/B
 (TTM)
: 
1.26  ?Current Ratio
 (TTM)
: 
2.51

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
8.01Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate GRFS Intrinsic Value

Common questions about GRFS valuation

Is Grifols, S.A. (GRFS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Grifols, S.A. (GRFS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is GRFS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GRFS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is GRFS’s P/E ratio?

You can see GRFS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for GRFS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is GRFS a good long-term investment?

Whether GRFS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

GRFS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.12
MARKETSnap

Trading Metrics:

Open: 8.08   Previous Close: 8.25
Day Low: 8   Day High: 8.25
Year Low: 6.19   Year High: 11.14
Price Avg 50: 8.71   Price Avg 200: 9.27
Volume: 758490   Average Volume: 664572

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates
30-03-2026 17:31
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates
Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following reports of deaths, harm, non-compliance
13-03-2026 16:41
Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following reports of deaths, harm, non-compliance
Grifols: I'm Very Happy To Add In 2026
11-03-2026 21:36
Grifols: I'm Very Happy To Add In 2026
Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript
26-02-2026 17:27
Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript
Grifols: Positive/Neutral Scenario Posits An Upside
08-12-2025 12:02
Grifols: Positive/Neutral Scenario Posits An Upside

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read